Logo image
Back
Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis
Journal article   Open access   Peer reviewed

Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis

Swara M. Sarvepalli, Ishani Kapoor, Kubra Sarici, Sunir J. Garg and Majda Hadziahmetovic
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), v 14(2), 100173
Mar 2025
DOI: https://doi.org/10.1016/j.apjo.2025.100173
PMID: 40037467
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.apjo.2025.100173View
Published, Version of Record (VoR) Open

Abstract

Anti-VEGF Best corrected visual acuity Intravitreal injection Neovascular age-related macular degeneration Photodynamic therapy Vitreoretinal disease
This study aimed to assess the role of photodynamic therapy (PDT) as an adjunct to anti-vascular endothelial growth factor (Anti-VEGF) intravitreal injections in the treatment of neovascular age-related macular degeneration (nvAMD). PubMed, Cochrane Library, and ClinicalTrials.gov were searched for keywords “macular degeneration” and “photodynamic therapy” and “placebo” or “ranibizumab” or “bevacizumab” or “aflibercept” from inception to 2023. Included studies were peer-reviewed primary data reporting 12-month treatment results of nvAMD with anti-VEGF and PDT, anti-VEGF alone, intravitreal triamcinolone, or placebo. 23 studies were included in the final analysis. The major outcomes were best-corrected visual acuity (BCVA), central retinal thickness (CRT), and injection burden at 12 months. Anti-VEGF + PDT had better BCVA at 12 months compared to anti-VEGF (MD −0.07; 95 % CI −0.12, −0.01; P = 0.02). There was no significant difference in CRT at 12 months in anti-VEGF + PDT group versus anti-VEGF (MD −3.66; 95 % CI −10.28, 2.98; P = 0.28). Anti-VEGF + PDT group had significantly fewer injections compared to anti-VEGF (MD −1.76; 95 % CI −1.95, −1.58; P < 0.0001). There was no significant difference in pooled ocular adverse events between anti-VEGF + PDT versus anti-VEGF (MD 0.96; 95 % CI 0.68, 1.36; P = 0.41). PDT is a successful adjunctive to anti-VEGF injections for the treatment of nvAMD. The combination of the therapies leads to improved BCVA at 12 months, decreased injection burden, and no difference in ocular safety.

Metrics

1 Record Views
4 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Ophthalmology
Logo image